ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

BMS Buys Stake In Innate Immunotherapy

by Lisa M. Jarvis
July 18, 2011 | APPEARED IN VOLUME 89, ISSUE 29

Bristol-Myers Squibb is shelling out $35 million up front and up to $430 million in milestones for access to IPH2102, a monoclonal antibody being developed by Innate Pharma. IPH2102 taps into a cancer patient’s own immune system by blocking the interaction between killer-cell immunoglobulin-like receptors and their ligands. Blocking the receptors activates natural killer cells that in turn destroy tumor cells. The drug is now in Phase I cancer trials. France-based Innate will continue to develop it through a Phase II trial for acute myeloid leukemia.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment